BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36735903)

  • 1. Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis.
    Sacco A; Desantis V; Celay J; Giustini V; Rigali F; Savino FD; Cea M; Soncini D; Cagnetta A; Solimando AG; D'Aliberti D; Spinelli S; Ramazzotti D; Almici C; Todoerti K; Neri A; Anastasia A; Tucci A; Motta M; Chiarini M; Kawano Y; Martinez-Climent JA; Piazza R; Roccaro AM
    Blood; 2023 May; 141(21):2615-2628. PubMed ID: 36735903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88.
    Sacco A; Federico C; Giacomini A; Caprio C; Maccarinelli F; Todoerti K; Favasuli V; Anastasia A; Motta M; Russo D; Rossi G; Bozza N; Castelli R; Neri A; Ronca R; Cattaneo C; Tucci A; Mor M; Presta M; Roccaro AM
    Blood; 2021 May; 137(18):2495-2508. PubMed ID: 33197938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.
    Tournilhac O; Santos DD; Xu L; Kutok J; Tai YT; Le Gouill S; Catley L; Hunter Z; Branagan AR; Boyce JA; Munshi N; Anderson KC; Treon SP
    Ann Oncol; 2006 Aug; 17(8):1275-82. PubMed ID: 16788002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the bone marrow in Waldenstrom macroglobulinemia.
    Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa GC; Leleu X; Roccaro AM
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S65-9. PubMed ID: 22035751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
    Leleu X; Jia X; Runnels J; Ngo HT; Moreau AS; Farag M; Spencer JA; Pitsillides CM; Hatjiharissi E; Roccaro A; O'Sullivan G; McMillin DW; Moreno D; Kiziltepe T; Carrasco R; Treon SP; Hideshima T; Anderson KC; Lin CP; Ghobrial IM
    Blood; 2007 Dec; 110(13):4417-26. PubMed ID: 17761832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.
    Sun H; Fang T; Wang T; Yu Z; Gong L; Wei X; Wang H; He Y; Liu L; Yan Y; Sui W; Xu Y; Yi S; Qiu L; Hao M
    J Transl Med; 2022 Dec; 20(1):576. PubMed ID: 36494694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
    Jalali S; Ansell SM
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
    Cholujova D; Beke G; Hunter ZR; Hideshima T; Flores L; Zeleznikova T; Harrachova D; Klucar L; Leiba M; Drgona L; Treon SP; Kastritis E; Dorfman DM; Anderson KC; Jakubikova J
    Int J Cancer; 2023 May; 152(9):1947-1963. PubMed ID: 36533670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
    Hodge LS; Ziesmer SC; Yang ZZ; Secreto FJ; Gertz MA; Novak AJ; Ansell SM
    Blood; 2012 Nov; 120(18):3774-82. PubMed ID: 22976953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
    Ho AW; Hatjiharissi E; Ciccarelli BT; Branagan AR; Hunter ZR; Leleu X; Tournilhac O; Xu L; O'Connor K; Manning RJ; Santos DD; Chemaly M; Patterson CJ; Soumerai JD; Munshi NC; McEarchern JA; Law CL; Grewal IS; Treon SP
    Blood; 2008 Dec; 112(12):4683-9. PubMed ID: 18216294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bone marrow microenvironment in Waldenström macroglobulinemia.
    Agarwal A; Ghobrial IM
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):218-21. PubMed ID: 23490994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.
    Jalali S; Price-Troska T; Paludo J; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Ansell SM
    Blood Adv; 2018 Aug; 2(15):1985-1997. PubMed ID: 30104397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
    Jalali S; Ansell SM
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel treatment options for Waldenström macroglobulinemia.
    Leblebjian H; Agarwal A; Ghobrial I
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.
    Shrimpton J; Care MA; Carmichael J; Walker K; Evans P; Evans C; de Tute R; Owen R; Tooze RM; Doody GM
    Blood Adv; 2020 Jun; 4(12):2821-2836. PubMed ID: 32574366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.
    Boutilier AJ; Huang L; Elsawa SF
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD40 in Waldenström's macroglobulinemia.
    Lee M; Advani R
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):87-9. PubMed ID: 19362983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
    Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
    Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
    Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
    Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.
    Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ
    Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.